IO Biotech Inc
IOBT0.664USD
+0.042+6.83%
收盘 12/19, 16:00（美东）报价延迟15分钟
46.31M总市值
亏损市盈率 TTM
关于 IO Biotech Inc 公司
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO Biotech Inc简介
公司代码IOBT
公司名称IO Biotech Inc
上市日期Nov 05, 2021
CEOZocca (Mai-Britt)
员工数量80
证券类型Ordinary Share
年结日Nov 05
公司地址Ole Maaloes Veh 3
城市COPENHAGEN
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Denmark
邮编2200
电话4570702980
网址https://www.iobiotech.com/
公司代码IOBT
上市日期Nov 05, 2021
CEOZocca (Mai-Britt)
IO Biotech Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Dr. Faical Miyara, Ph.D.
Dr. Faical Miyara, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Novo Holdings A/S
3.49%
其他
57.32%
持股股东
持股股东
占比
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Novo Holdings A/S
3.49%
其他
57.32%
股东类型
持股股东
占比
Venture Capital
32.61%
Investment Advisor
6.58%
Hedge Fund
5.28%
Individual Investor
5.14%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.26%
其他
46.76%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
2023Q2
46
22.57M
78.34%
-5.75M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Lundbeckfond Ventures
13.95M
21.18%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
10.35%
--
--
Apr 11, 2025
HBM Partners AG
3.94M
5.99%
--
--
Apr 11, 2025
Novo Holdings A/S
2.51M
3.81%
-842.00K
-25.10%
Aug 11, 2025
Marshall Wace LLP
2.11M
3.2%
--
--
Jun 30, 2025
BofA Global Research (US)
1.62M
2.45%
-36.44K
-2.21%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
653.68K
0.99%
-135.78K
-17.20%
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
IO Biotech Inc的前五大股东是谁？
IO Biotech Inc 的前五大股东如下：
Lundbeckfond Ventures持有股份：13.95M，占总股份比例：21.18%。
Kurma Partners SA持有股份：6.82M，占总股份比例：10.35%。
HBM Partners AG持有股份：3.94M，占总股份比例：5.99%。
Novo Holdings A/S持有股份：2.51M，占总股份比例：3.81%。
Marshall Wace LLP持有股份：2.11M，占总股份比例：3.20%。
Lundbeckfond Ventures持有股份：13.95M，占总股份比例：21.18%。
Kurma Partners SA持有股份：6.82M，占总股份比例：10.35%。
HBM Partners AG持有股份：3.94M，占总股份比例：5.99%。
Novo Holdings A/S持有股份：2.51M，占总股份比例：3.81%。
Marshall Wace LLP持有股份：2.11M，占总股份比例：3.20%。
IO Biotech Inc的前三大股东类型是什么？
IO Biotech Inc 的前三大股东类型分别是：
Lundbeckfond Ventures
Kurma Partners SA
HBM Partners AG
Lundbeckfond Ventures
Kurma Partners SA
HBM Partners AG
有多少机构持有IO Biotech Inc(IOBT)的股份？
截至2025Q3，共有49家机构持有IO Biotech Inc的股份，合计持有的股份价值约为42.06M，占公司总股份的63.84%。与2025Q2相比，机构持股有所增加，增幅为-2.94%。
哪个业务部门对IO Biotech Inc的收入贡献最大？
在--，--业务部门对IO Biotech Inc的收入贡献最大，创收--，占总收入的--%。
